A Randomized Phase II Study of Sorafenib Maintenance in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC) After Response to Induction Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Sep 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 15 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.